Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 5/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CETP | P11597 | 6/20 | 0.48 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3138634 | 0.88 | PTGES (0.52) | PTGESRXFP1MAPTCETPPPARG | |
| SCHEMBL3128346 | 0.78 | RAB9A (0.47) | RXFP1MAPTCETPP2RY14 | |
| SCHEMBL3137146 | 0.77 | PTGES (0.58) | PTGESRXFP1MAPTCETPPPARG | |
| SCHEMBL3133366 | 0.76 | CETP (0.50) | RXFP1MAPTCETPP2RY14PPARG | |
| SCHEMBL4498498 | 0.76 | PTGES (0.81) | PTGESMAPTPPARG | |
| SCHEMBL3145582 | 0.76 | PTGES (0.52) | PTGESRXFP1MAPTPPARG | |
| SCHEMBL3131397 | 0.70 | PTGES (0.56) | PTGESRXFP1MAPTCETP | |
| SCHEMBL3131388 | 0.70 | PTGES (0.56) | PTGESRXFP1MAPTCETP | |
| SCHEMBL4506643 | 0.69 | PTGES (0.83) | PTGESMAPT | |
| SCHEMBL4512212 | 0.69 | TP53 (0.65) | RXFP1MAPTP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004301-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004301-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | PTGES 162/4885RXFP1 717/4885MAPT 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.